696
Views
0
CrossRef citations to date
0
Altmetric
Corrections

Correction

This article refers to:
Fomepizole as an adjunct in acetylcysteine treated acetaminophen overdose patients: a case series

The original abstract for this article has now been replaced and revised as follows:

Article title: Fomepizole as an adjunct in acetylcysteine treated acetaminophen overdose patients: a case series

Authors: Link, S. L., Rampon, G., Osmon, S., Scalzo, A. J. & Rumack, B. H.

Journal: Clinical Toxicology

DOI: http://dx.doi.org/10.1080/15563650.2021.1996591

Introduction: Acetaminophen (N-acetyl-para-aminophenol or APAP) is the leading cause of acute liver failure worldwide. Standard therapy for APAP overdose is with IV N-acetylcysteine (NAC). However, overdose patients treated with NAC can still incur hepatotoxicity in some circumstances. Fomepizole has proven safety in methanol and ethylene glycol poisoning and is a potent CYP2E1 and c-Jun-N-terminal Kinase (JNK) inhibitor that is effective even in the metabolic phase.

Methods: We present a prospective case series of 14 consecutive, high-risk patients who had elevated APAP levels after overdose who were treated with fomepizole as an adjunct to standard IV-NAC. The attending toxicologist utilized clinical judgement to determine the use of fomepizole, especially if APAP levels persisted due to altered half-life or risk factors for toxicity.

Results: There were no unfavorable outcomes in any patient, which were better than expected.

Conclusions: This case series has demonstrated the safety of fomepizole in high-risk APAP overdose. The efficacy of fomepizole needs to be further elucidated through controlled clinical trials on a larger scale. In massive APAP overdoses, fomepizole should be considered as an adjunct due to the known failure rate of NAC and the safety profile of fomepizole.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.